From: The prevalence of human papillomavirus in pediatric tonsils: a systematic review of the literature
First Study Author & Year of Publicationa | Country | # of Patients | Age Range (Years) [mean] | Prevalence of HPVa | Testing Method | Types of HPV Tested | Types of HPV Found |
---|---|---|---|---|---|---|---|
Cockerill, CC (2016) [25] [full text] b | USA | 129 | 1ā12 [NR] | 0% | Biopsy + swabs + Roche Cobas Amplicor test qPCR & E6/E7 Gene-Probe Aptima HPV test | 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 | None |
Palmer, E (2014) [27] [full text] | United Kingdom | 1670 | 0ā18 [NR] | 0% | Biopsy + GP5+/6+ primer PCR enzyme immunoassay + PCR E6 gene targeting for HPV16 | 20 types (unspecified), 14 high-risk and 6 low-risk | None |
Xue, XC (2014) [26] [full text] | China | 42 | 3ā12 [6.8] | 0% | Biopsy + MY09/11 primer qPCR | 6, 11, 16, 18, 26, 31, 33ā35, 39, 40, 42ā45, 51ā59, 61, 66ā73, 81ā84 | None |
Sun, YF (2012) [abstract] [article in Chinese] [14] [full text] | China | 177 | NR[NR] | 1% | Biopsy + PCR (unspecified) | NR | 6, 11 |
Duray, A (2011) [19] [full text] | Belgium | 42 | 0ā15 [NR] | 21% | Biopsy + GP5+/GP6+ primer PCRā+āE6/E7 type-specific qPCR for multiple HPV subtypes | 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 | 16, NR |
Baloglu, H (2010) [17] [full text] | Turkey | 165 | 5ā21 [11.9] | 7% | Biopsy + MY/GP PCRā+āE6/E7 type-specific PCR | 6, 11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56, 58, 59, 66, 68 | 6, 11, 16, 31 |
SoldatskiÄ, IuA (2009) [abstract] [article in Russian] [13] | Russia | 8 | 2ā14 [6.8] | 13% | PCR | 6, 11, 16, 18, 31, 33 | NR |
Mammas, IN (2006) [20] [full text] | Greece | 64 | 2ā14 [7.1] | 9% | Biopsy + GP5+/6+ primer PCRā+ātype-specific PCR for multiple HPV subtypes | 11, 16, 18, 33 | 16, NR |
Sisk, J (2006) [18] [full text] | USA | 50 | 3ā12 [NR] | 4% | Biopsy + MY09/11 primer PCR | NR | 11 |
Ribeiro, KM (2006) [37] [full text] | Brazil | 100 | 2ā13 [NR] | 0% | Biopsy + MY09/11 primer PCR | NR | None |
Chen, R (2005) [21] [full text] | Finland | 73 | 1ā16 [8.3] | 8% | Biopsy + GP5+/6+ & MY09/11 primer PCRā+ātype-specific testing | NR | 16 |